Inclusion Criteria:  Participants >= 18 years of age diagnosed with intestinal failure due to SBS as a result of intestinal resection. SBS-IF participants treated with teduglutide according to Summary of Product Characteristics (SmPC). Patients who receive or have received teduglutide for at least six months at the date of inclusion (from treatment initiation to inclusion date, date of discontinuation, death for any cause or loss of follow-up). When required by the ethics committee of the center: participants who have signed the informed consent form (ICF) to participate in the study.  Exclusion Criteria:  - Participants who do not meet the inclusion criteria.